Dianthus Therapeutics Inc. (DNTH) saw its stock price soar 5.09% during intraday trading on Tuesday, driven by positive analyst sentiment.

The surge follows a series of analyst upgrades and significant price target increases. Wedbush raised its price target on Dianthus to $80 from $55 while maintaining an Outperform rating. Raymond James upgraded the stock to Strong Buy from Outperform and more than doubled its price target to $123 from $63. Additionally, Baird raised its price target to $132 from $67, keeping an Outperform rating on the shares.

These coordinated analyst actions reflect growing confidence in the company's prospects and have contributed to increased investor buying activity during the trading session.